+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Orphan Drug"

Drug Repurposing Market 2024-2028 - Product Thumbnail Image

Drug Repurposing Market 2024-2028

  • Report
  • October 2024
  • 198 Pages
  • Global
From
From
Strategic Intelligence: Orphan Designated Drugs - Product Thumbnail Image

Strategic Intelligence: Orphan Designated Drugs

  • Report
  • August 2024
  • 54 Pages
  • Global
From
Drug Discovery Outsourcing Market Report 2023-2033 - Product Thumbnail Image

Drug Discovery Outsourcing Market Report 2023-2033

  • Report
  • June 2023
  • 389 Pages
  • Global
From
Orphan Drugs Market Report 2023-2033 - Product Thumbnail Image

Orphan Drugs Market Report 2023-2033

  • Report
  • October 2023
  • 258 Pages
  • Global
From
From
Orphan Drugs Market - Product Thumbnail Image

Orphan Drugs Market

  • Report
  • January 2024
  • 189 Pages
  • Global
From
Orphan Drug Growth Opportunities - Product Thumbnail Image

Orphan Drug Growth Opportunities

  • Report
  • March 2024
  • 78 Pages
  • Global
From
Orphan Drugs Global Market Report 2024 - Product Thumbnail Image

Orphan Drugs Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
Avexitide Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Avexitide Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • July 2023
  • 30 Pages
  • Global
From
Tofersen Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Tofersen Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
Reldesemtiv Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Reldesemtiv Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
Loading Indicator

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more